Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant RP2 + FLOT in Stage II+ Non-metastatic Gastroesophageal Adenocarcinoma
NCT07059611Phase 2Not yet recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2027
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of sturlimogene erparepvec in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Abramson Cancer Center. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
sturlimogene erparepvec
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07059611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059611.